SCHEMBL1419908

SCHEMBL1419908

CCOC(=O)c1cccn2nc(-c3cccc(C(F)(F)F)c3)nc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 6/20 0.50
MEN1 O00255 1/20 0.50
MAPT P10636 1/20 0.50
KMT2A Q03164 1/20 0.50
XPO1 O14980 1/20 0.49
KDM4E B2RXH2 5/20 0.46
HPGD P15428 2/20 0.46
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.46
DHODH Q02127 1/20 0.46
PARP1 P09874 1/20 0.46
TSHR P16473 1/20 0.46
CASP1 P29466 1/20 0.46
CASP7 P55210 1/20 0.46
HSD17B10 Q99714 1/20 0.46
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
BRAF P15056 2/20 0.44
GRM5 P41594 1/20 0.43
GRIN1 Q05586 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1420197 0.84 DHODH (0.65) CSNK1DMEN1KMT2AKDM4EHPGD
SCHEMBL1419900 0.80 KDM4E (0.50) MEN1MAPTKMT2AXPO1KDM4E
SCHEMBL2844449 0.79 TSHR (0.45) MAPTKDM4EHPGDALDH1A1GAA
SCHEMBL1085058 0.74 MAPT (0.58) MEN1MAPTKMT2AXPO1KDM4E
SCHEMBL14640840 0.74 MAPT (0.53) MEN1MAPTKMT2AXPO1KDM4E
SCHEMBL10961325 0.74 FAAH (0.54) MEN1MAPTKMT2AXPO1KDM4E
SCHEMBL10989292 0.74 MEN1 (0.53) MEN1MAPTKMT2AXPO1KDM4E
SCHEMBL30504027 0.74 FAAH (0.54) MEN1MAPTKMT2AXPO1KDM4E
SCHEMBL11565909 0.73 MAPT (0.53) MEN1MAPTKMT2AKDM4EHPGD
SCHEMBL1855999 0.73 JAK2 (0.56) KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077248-A1 IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. 2011-03-31 US disclosed
US-20110077248-A1 IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. 2011-03-31 US disclosed
US-20110077248-A1 IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. 2011-03-31 US disclosed
EP-2297144-A1 IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS Sirtris Pharmaceuticals, Inc. (US) 2011-03-23 EP disclosed
WO-2009146358-A1 IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2009-12-03 WO disclosed
WO-2009146358-A1 IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2009-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110077248-A1 IMIDAZOPYRIDINE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRT3, SIRT1, SIRT2 CSNK1D 2893/4885MEN1 3970/4885MAPT 1015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.